CSL LIMITED TO APPLY FOR LICENSE TO MARKET INFLUENZA VACCINE IN THE U.S.; MAJOR VACCINE MANUFACTURER TO DOUBLE CAPACITY

CSL Limited, a global, specialtybiopharmaceutical company headquartered in Melbourne, Australia, todayannounced plans to introduce its influenza vaccine into the U.S.market. Speaking at Merrill Lynch's Global Pharmaceutical andBiotechnology Conference here, CSL Chief Executive Officer andManaging Director Dr. Brian McNamee said, "CSL is the leading producerof influenza vaccine in the Southern Hemisphere and has a longheritage in biological research and manufacture.

Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=370788)